Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MXCT NYSE:RENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$1.83+10.9%$1.49$1.26▼$5.20$175.90M1.23851,544 shs738,582 shsRENXRelx$21.19$0.00$20.06▼$23.30N/AN/A100,590 shs547,934 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte+3.12%+6.45%+13.79%-22.17%-57.36%RENXRelx0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$1.83+10.9%$1.49$1.26▼$5.20$175.90M1.23851,544 shs738,582 shsRENXRelx$21.19$0.00$20.06▼$23.30N/AN/A100,590 shs547,934 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte+3.12%+6.45%+13.79%-22.17%-57.36%RENXRelx0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMXCTMaxCyte 2.20Hold$7.00282.51% UpsideRENXRelx 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest YGEN, OSL, MXCT, and RENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025MXCTMaxCyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MXCTMaxCyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/11/2025MXCTMaxCyteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/7/2025MXCTMaxCyteWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/22/2025MXCTMaxCyteStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMXCTMaxCyte$38.63M5.05N/AN/A$1.95 per share0.94RENXRelxN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMXCTMaxCyte-$41.06M-$0.430.00N/AN/A-125.22%-22.12%-19.10%11/5/2025 (Estimated)RENXRelxN/A$1.2217.37∞N/AN/AN/AN/AN/ALatest YGEN, OSL, MXCT, and RENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025MXCTMaxCyte-$0.11N/AN/AN/A$8.37 millionN/A8/6/2025Q2 2025MXCTMaxCyte-$0.10-$0.12-$0.02-$0.12$9.57 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMXCTMaxCyteN/AN/AN/AN/AN/ARENXRelx$0.281.32%N/A22.95%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMXCTMaxCyteN/A12.4011.71RENXRelxN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMXCTMaxCyte68.81%RENXRelx1.37%Insider OwnershipCompanyInsider OwnershipMXCTMaxCyte3.30%RENXRelxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMXCTMaxCyte80106.61 million103.09 millionOptionableRENXRelxN/AN/AN/ANot OptionableYGEN, OSL, MXCT, and RENX HeadlinesRecent News About These CompaniesRexShares' REX-Osprey ETFs Help Bridge The Opportunity Gap For Prospective Crypto InvestorsOctober 15 at 9:03 AM | benzinga.comReba McEntire Engaged to Rex Linn; And Dolly Parton Is Who To ThankOctober 14 at 10:56 PM | yahoo.comReba McEntire’s Fiancé Rex Linn Just Made a Blink-and-Miss-It Cameo on The VoiceOctober 14 at 3:38 AM | msn.com‘Rex – Vienna Calling' Starts Production With Beta Film, MR Film, Seven.One and ORF on BoardOctober 13 at 10:35 PM | msn.comRex Nelson's high school football rankings: After seven weeksOctober 13 at 5:33 PM | arkansasonline.comA‘Rex – Vienna Calling’ Starts Production With Beta Film, MR Film, Seven.One and ORF on BoardOctober 13 at 2:22 AM | variety.comVShedeur Sanders responds to Rex Ryan's 'embarrassment' criticisms, explains recent 'mime' actOctober 11, 2025 | msn.comJudge grants bid from convicted murderer John Bittrolf to compare DNA from crime scene to DNA from accused Gilgo serial killer Rex HeuermannOctober 11, 2025 | newsday.comNShedeur Sanders responds to Rex Ryan’s criticism — this time without mimingOctober 11, 2025 | sports.yahoo.comShedeur Sanders Responds to Criticism of Browns QB Trolling Rex Ryan on VideoOctober 10, 2025 | bleacherreport.comBBrowns' Shedeur Sanders offers real response to fiery Rex Ryan criticismsOctober 10, 2025 | msn.comRex Ryan Rips Shedeur SandersOctober 9, 2025 | msn.comESPN NFL Analyst Rex Ryan Emerging For NFL Head Coaching JobOctober 8, 2025 | msn.comRex Guthrie's 'subtle' athleticism, and his rise to becoming a Nebraska starterOctober 7, 2025 | journalstar.comJESPN’s Rex Ryan Is Taking Heat For Calling Black NFL Player “Homeboy” On Live TV [VIDEO]October 7, 2025 | totalprosports.comTRex Ryan Doesn't Hold Back On NFL Team's Coaches: 'They Have No Confidence'October 7, 2025 | sports.yahoo.com‘I hate it’: Rex Ryan reluctantly credited Mike Vrabel for ‘night and day’ Patriots turnaroundOctober 7, 2025 | msn.comRex Nelson's college football picks: Week 7October 7, 2025 | arkansasonline.comAReba McEntire Talked About Marriage with Rex Linn Years Before Their EngagementOctober 7, 2025 | msn.comT-Rex Action Figure Review — Prepare to Be AmazedOctober 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYGEN, OSL, MXCT, and RENX Company DescriptionsMaxCyte NASDAQ:MXCT$1.83 +0.18 (+10.91%) Closing price 04:00 PM EasternExtended Trading$1.78 -0.05 (-2.73%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Relx NYSE:RENXRELX NV, through its interest in RELX Group plc, provides information and analytics for professional and business customers across industries worldwide. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment offers information and analytics to institutions and professionals. The Risk & Business Analytics segment provides solutions and decision tools that combine public and industry specific content with technology and analytics to evaluate and predict risk, as well as enhance operational efficiency. The Legal segment offers legal, regulatory, and business information and analytics. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier NV and changed its name to RELX NV in June 2015. RELX NV was incorporated in 1880 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
